4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients who are particularly at risk.

The combination of nirmatrelvir and ritonavir has been approved since January 2022 for the treatment of adults with COVID-19 who do not require additional oxygen supply and are at an increased risk of developing a severe course of COVID-19. In an early benefit assessment, the IQWiG has examined whether the use of the combination in patients who are at risk provides an additional clinical benefit compared to the appropriate comparator therapy.

Read IQWiG press release [German]